Table 3.
FR-α expression in primary tumor samples subdivided into histologic subtype. Non-serous carcinomas are further subdivided; shown in italic
| Tumor type | N | FR-α– | FR-α+ | Weak (1) | Moderate (2) | Strong (3) |
|---|---|---|---|---|---|---|
| Serousa | 165 | 30 | 135 | 88 | 38 | 9 |
| 18.2% | 81.8% | 53.3% | 23% | 5.5% | ||
| All othera | 51 | 31 | 20 | 14 | 5 | 1 |
| 60.8% | 39.2% | 27.5% | 9.8% | 2.0% | ||
| Mucinous | 11 | 5 | 6 | 4 | 2 | 0 |
| 45.5% | 54.5% | 36.4% | 18.2% | |||
| Endometrioid | 32 | 25 | 7 | 4 | 3 | 0 |
| 78.1% | 21.9% | 12.5% | 9.4% | |||
| Clear-cell | 5 | 1 | 4 | 4 | 0 | 0 |
| 20% | 80% | 80% | ||||
| Undifferentiated | 3 | 0 | 3 | 2 | 0 | 1 |
| 66.7% | 33.3% | |||||
| Missing | 35 |
N; number of cases per group
FR-α–; the number and percentage of samples showing no FR-α expression (negative)
FR-α+; the number and percentage of samples showing FR-α expression. These are further subdivided into weak (1), moderate (2) and strong (3) expression (right half of table)
aFR-α expression in serous compared to non-serous carcinomas: p < 0.001